
Epic Sciences hires regulatory affairs VP
pharmafile | September 17, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | epic sciences, paul frieberg
San Diego-based cancer diagnostics firm Epic Sciences has appointed Glen Paul Freiberg as its vice president of regulatory affairs and quality assurance.
Freiberg has more than 35 years of FDA-related experience throughout his career, which began as an FDA investigator in New England where he specialised in clinical trials, drug, medical device and diagnostic regulations.
He has held positions of increasing responsibility at The Upjohn Company, The Coulter Corporation, Curtin Matheson Scientific, Boehringer Mannheim and Oncor. He has also served as vice president of clinical, regulatory and quality at SpectraScience, and vice president of regulatory affairs and quality assurance at Eveia Medical and Alphatec Spine.
“Glen brings to Epic an invaluable breadth of regulatory experience, starting with his career as an FDA investigator to leading the clinical and regulatory strategies for the approval of innovative and novel molecular diagnostics,” says Murali Prahalad, president and chief executive of Epic Sciences.
“I look forward to helping Epic advance through regulatory approvals for a new type of cancer diagnostic technology that can monitor and personalise therapies at clinical decision points,” adds Freiberg.






